Harding Jessica L, Hu Chengcheng, Varghese Jithin Sam, Carrillo-Larco Rodrigo M, Ali Mohammed K
Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA; Health Services Research Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA; Health Services Research Center, Emory University School of Medicine, Atlanta, GA, USA.
Diabetes Metab. 2025 Jul;51(4):101659. doi: 10.1016/j.diabet.2025.101659. Epub 2025 May 13.
We compared diabetes prevalence, awareness, and control pre versus post the Covid-19 pandemic.
This was a cross-sectional analysis of the U.S. National Health and Nutrition Examination Surveys pre (2017-2020) and post (2021-2023) the pandemic. We included all non-pregnant adults (aged ≥ 20 years) who had undergone biomedical testing. Diagnosed and undiagnosed diabetes was defined as self-reported diabetes and no self-reported diabetes with HbA1c >6.5 % or fasting plasma glucose ≥126 mg/dL, respectively. Among diagnosed diabetes, we estimated proportions achieving glycemic (HbA1c < 7.0 %), blood pressure (< 130/80 mmHg), and cholesterol control (non-high-density lipoprotein < 130mg/dl), and use of blood pressure and lipid lowering medications.
The prevalence of total diabetes, diagnosed diabetes, undiagnosed diabetes, and proportion of diabetes that was undiagnosed remained stable between pre and post pandemic periods: from 16.2 % [95 %CI: 14.3-18.1] to 15.8 % [13.7-17.9], from 11.7 % [10.1-13.2] to 11.3 % [9.4-13.2], from 4.6 % [3.8-5.3]) to 4.5 % [3.4-5.6]), and from 28.1 % [24.3-31.8] to 28.4 % [21.9-35.0], respectively. Among those with diagnosed diabetes, glycemia, blood pressure, lipid control, and use of blood pressure or lipid medication did not significantly change.
Between 2017-2020 and 2021-2023, there were no significant changes in diabetes prevalence, awareness, and control in the U.S.
我们比较了新冠疫情前后的糖尿病患病率、知晓率和控制情况。
这是一项对美国国家健康与营养检查调查在疫情前（2017 - 2020年）和疫情后（2021 - 2023年）进行的横断面分析。我们纳入了所有接受过生物医学检测的非妊娠成年人（年龄≥20岁）。已诊断和未诊断的糖尿病分别定义为自我报告患有糖尿病以及未自我报告糖尿病但糖化血红蛋白>6.5%或空腹血糖≥126mg/dL。在已诊断糖尿病患者中，我们估计了实现血糖控制（糖化血红蛋白<7.0%）、血压控制（<130/80mmHg）和胆固醇控制（非高密度脂蛋白<130mg/dl）的比例，以及使用降压和降脂药物的情况。
疫情前后，总体糖尿病患病率、已诊断糖尿病患病率、未诊断糖尿病患病率以及未诊断糖尿病所占比例均保持稳定：分别从16.2%[95%置信区间：14.3 - 18.1]降至15.8%[13.7 - 17.9]，从11.7%[10.1 - 13.2]降至11.3%[9.4 - 13.2]，从4.6%[3.8 - 5.3]降至4.5%[3.4 - 5.6]，从28.1%[24.3 - 31.8]降至28.4%[21.9 - 35.0]。在已诊断糖尿病患者中，血糖、血压、血脂控制情况以及降压或降脂药物的使用情况均无显著变化。
在2017 - 2020年至2021 - 2023年期间，美国的糖尿病患病率、知晓率和控制情况没有显著变化。
